INTERACTION OF ¹²⁵ I-LABELLED COMPLEMENT SUBCOMPONENTS CTr AND CTs WITH PROTEASE INHIBITORS IN PLASMA

R. B. SIM*, A. REBOUL, G. J. ARLAUD, C. L. VILLIERS and M. G. COLOMB

DRF/Biochimie, Centre d'Etudes Nucléaires de Grenoble, 85 X, 38041, Grenoble Cedex, and Université Scientifique et Médicale de Grenoble, France

Received 4 October 1978

1. Introduction

Activation of the classical pathway of the complement system is brought about by the binding of the first component of complement, C1, to antibody antigen complexes. C1 is a glycoprotein complex, containing 3 types of subunits, Clq, Clr and Cls, of which the two latter are serine protease zymogens [1]. The interaction of C1q with antibody in immune complexes leads to the sequential activation of C1r and C1s by limited proteolysis [2]. The proteases C1r and C1s are both of mol. wt 83 000, and have structures similar to that of plasmin [3]. As with other plasma proteases, the activities of C1r and C1s are regulated by protease inhibitors. In plasma there are 7 well-characterised protease inhibitors, each capable of inhibiting several serine proteases [7,8]. Additional plasma serine protease inhibitors have been described [7]. Although Clr and Cls are both known to form stable complexes with C1 inhibitor (C1 In) [4,5], little information is available on their activity towards other protease inhibitors. A simple, and widely applicable technique, involving incubation of 125Ilabelled C1r and C1s with plasma, followed by gel filtration, affinity chromatography and SDS-polyacrylamide gel analyses has been used to investigate

Abbreviations SDS, sodium dodecyl sulphate, BSA, bovine serum albumin, EDTA, ethylene diamine tetraacetic acid, The nomenclature of complement components is that recommended by the World Health Organization (1968)

Present address MRC Immunochemistry Unit, Department of Biochemistry, University of Oxford, South Parks Rd, Oxford OX1 3QU, England the interaction of $\overline{C1r}$ and $\overline{C1s}$ with inhibitors in whole plasma. The results demonstrate, consistent with the very restricted proteolytic specificity of $\overline{C1r}$ and $\overline{C1s}$, that $\overline{C1}$ In is the only physiological inhibitor of both proteases. The iodination procedure used does not detectably alter any of the activities of the two enzymes.

2. Materials and methods

2.1. Proteins

Human citrated plasma was obtained from the Centre de Transfusion Sanguine, Grenoble. Preparation of serum [9] and the isolation of $\overline{C1}$ In [4], $\overline{C1}$ r and $\overline{C1}$ s [1,10] were as previously described. Purified proteins were quantified from their specific A_{280} , using $E_{1~\rm cm}^{1\%}=4.5$, 11.5 and 9.4, respectively, for $\overline{C1}$ In, $\overline{C1}$ r and $\overline{C1}$ s [3,11].

2.2. Anti-C1 in antibody linked to Sepharose 6B

The total immunoglobulin fraction was precipitated from 5 ml rabbit anti C1 In antiserum (Behring) and coupled to 10 ml (packed volume) of cyanogen bromide-activated Sepharose 6B. Coupling yield was 70%. Procedures were as in [12].

2.3. Iodination

Iodination of $\overline{C1r}$ and $\overline{C1s}$ was done by a modification of the C1q-labelling method in [13]. Solutions of $\overline{C1s}$ (500 μ g/ml) or $\overline{C1r}$ (250 μ g/ml) in 5 mM triethanolamine—HCl, 145 mM NaCl (pH 7.4) were chilled to 0°C, and the following quantities of reagents, made up in the same buffer, were added per

1 ml protein solution 50 µl 20 µM NaI, 50 µl Na¹²⁵I (Amersham) adjusted to spec. act. $0.5 \mu \text{C}_1/\text{m}1, 50 \mu \text{l}$ 2 mg/ml lactoperoxidase (Calbiochem, Grade B) and $20 \,\mu l \, 1/20\,000 \, dilution of 30\% \, H_2O_2$. After 50 min incubation at 0°C, free 125 I was removed from the mixture by gel filtration on a column (25 × 1 cm) of Sephadex G-50 in 5 mM triethanolamine – HCl, 145 mM NaCl, 0.02% w/v NaN₃ (pH 7.4). The labelled protein was pooled, dialysed against 11 of the gel filtration buffer, and stored at 4°C. 125 I was counted on an Intertechnique CG 2000 gamma counter. The activities of the labelled proteins were verified in the following functional tests $\overline{C1s} \alpha - N$ benzyloxycarbonyl-L-lysine p-nitrophenol esterase activity [3], C1r acetyl arginine methyl esterase activity [14], capacity of C1r to activate proenzymic C1s [3]; subcomponent C1r and C1s haemolytic activity [9], and the specific and sequential binding of C1r then C1s to antibody—antigen—C1q complexes [2,15]. In addition, the rates of reaction of labelled and unlabelled C1r and C1s with C1 In were compared (see fig.1).

2.4. Protease-protease inhibitor Interactions

The interaction of Clr of Cls with protease inhibitors was studied by adding 25 μ g or 250 μ g C1r or C1s, containing in each case 2 × 10⁵ cpm ¹²⁵I-labelled material, to 500 µl citrated plasma or to 500 µl serum in the presence of 5 mM CaCl₂ or 5 mM EDTA. The two concentrations of labelled protease used were chosen to be respectively less than, and greater than, the total inhibitory capacity of C1 In in plasma. Soybean trypsin inhibitor (1 mg/ml) 100 µl was added to limit proteolysis by other proteases present in plasma. Control experiments were performed in which 500 µl 5 mM triethanolamine-HCl, 145 mM NaCl (pH 6.4) containing 150 µg C1 In + 15 mg BSA was used instead of plasma. Samples were incubated 1 h, 37°C, and the size distribution of the labelled species in each sample was then examined by gel filtration on Ultrogel AcA-34. All eluate fractions containing radioactivity were pooled and passed through a column of anti-C1 In antibody linked to Sepharose-6B. Radioactive material not binding to this column was pooled, concentrated to 1 ml by ultrafiltration, and the remaining labelled species were reexamined on the Ultrogel AcA-34 column. Peaks of radioactivity eluted from Ultrogel were

pooled individually, concentrated to a small volume, and their composition was analysed by SDS—polyacrylamide gel electrophoresis. Material bound to the anti-CI In column was eluted with 1 M NH₄SCN, dialysed against the chromatography buffer, and examined on SDS—polyacrylamide gels.

Preparation of samples for SDS—polyacrylamide gel electrophoresis, the electrophoresis system, and gel staining were as in [3]. Gels stained with Coomassie blue were scanned [12] and cut into 2 mm slices for ¹²⁵I counting.

Determination of hydrodynamic parameters by sucrose density gradient centrifugation and gel filtration was as in [3].

3. Results and discussion

3.1. Iodination

Iodination of CIr and CIs resulted in 35-40%




Fig 1 Comparison of the rates of reaction of iodinated and non-iodinated CIr and CIs with CI In. 125 I-labelled CIr or C1s were diluted with cold C1r or C1s such that the overall labelling represented 5 atoms I/100 molecules C1r or C1s. The $\overline{C1r}$ (450 $\mu g/ml$) or $\overline{C1s}$ (440 $\mu g/ml$) in 5 mM triethanolamine-HCl, 145 mM NaCl, 5 mM EDTA (pH 7 4) was then incubated with C1 In (920 µg/ml) at 37°C Reaction was stopped at various times by placing 50 µl of the reaction mixture in 50 μ l 0 2 M Tris-HCl, 8 M urea, 2% w/v SDS, 40 mM 10doacetamide (pH 8 0) and incubating 4 min at 100°C Samples were then examined on SDS-polyacrylamide gels, and the gels stained and scanned The rate of uptake of total (i.e., labelled + unlabelled CIr or CIs into complexes with CI In (•) was estimated from the decrease in intensity of the free C1r or C1s peaks on the gels Gels were then sliced and the rate of complexation of labelled C1r or C1s with C1 In (0) calculated from the radioactivity associated with the free protease and C1 In-protease complex bands

incorporation of the total radioactivity supplied for C1r, and 40-45% for C1s, corresponding to final spec. act. 2.9–3.3 μ Ci/nmol for CTr and 1.7–1.9 μ C₁/nmol for C1s. In C $\overline{1}$ r, 66-70% of the total labelling is in the light (B) polypeptide chain, while for $\overline{C1}$ s, 93–95% is in the heavy (A) chain. None of the binding or enzymic activities of $\overline{C1r}$ or C1s was detectably altered by iodination. The rate of interaction of the labelled proteases with $\overline{C1}$ in (fig.1) was identical to the rate observed with total (i.e., labelled + unlabelled) material showing that iodination is again without affect on this activity. It has been shown [16] that iodination of C1s may lead to loss of reactivity with C1 In, and possibly to altered capacity to interact with other C1 subcomponents. The iodination procedure described above is, however, done with considerably lower quantities of oxidising agent than in [16].

The same iodination procedure is applicable to proenzymic C1r and C1s, with which similar iodination yields are obtained.

3.2. Protease-protease inhibitor interactions

All of the well-characterised plasma protease inhibitors (α_1 antitrypsin, α_2 macroglobulin, C1 In, inter- α -trypsin inhibitor, α_2 antiplasmin, antichymotrypsin and antithrombin III) inhibit proteases by forming complexes with them [6,7]. These complexes are stable during gel filtration, and also (with the exception of α_2 macroglobulin-protease complexes) during SDS-polyacrylamide gel electrophoresis. Incubation of 125 I-labelled CIr or CIs with plasma, followed by gel filtration demonstrates (fig.2) that Clr and Cls are taken up into complexes of higher molecular weight during incubation. In this gel filtration system free C1s behaves as an 83 000 mol. wt monomer while CIr is a 166 000 mol, wt dimer [3]. With additions of 25 μ g C1r or C1s to plasma, nearly all of each protease becomes complexed (fig.2b,d) while with 250 μ g additions much of the C1r and C1s added does not form higher molecular weight complexes. Elution profiles of radioactivity from samples incubated with plasma, with serum in the presence of Ca2+ or EDTA, or control samples incubated with C1 in were all very similar.

Passage of the pool of radioactive fractions from Ultrogel through the column of anti-C1 In resulted in retention of a percentage of the radioactivity




Fig 2. First gel filtration analysis of complex formation Samples were run on a column (48 × 1 cm) of Ultrogel AcA 34 in 5 mM triethanolamine—HCl, 145 mM NaCl, 5 mM EDTA The elution profile of radioactivity (———) and of A_{280} (———) shown for samples of proteases incubated with plasma. (A) 250 μ g CIr, (B) 25 μ g CIr, (C) 250 μ g CIs, (D) 25 μ g CIs. The elution positions of free labelled CIr and CIs, run as standards, are shown by arrows. V_0 = void volume.

Table 1
Percentage retention of ¹²⁵I-labelled C1r or ¹²⁵I-labelled C1s on Sepharose-anti C1 In

Sample	% Radioactivity retained
C1r (25 µg) + plasma	72
$C\overline{1}r$ (25 μ g) + $C\overline{1}$ In + BSA	77
Cīs (25 µg) + plasma	81
$C\overline{l}s$ (25 μg) + $C\overline{l}$ In + BSA	85
C1r (250 µg) + plasma	26
$C\overline{1}r (250 \mu g) + C\overline{1} In + BSA$	29
$C1s (250 \mu g) + plasma$	31
$C\overline{1}s (250 \mu g) + C\overline{1} In + BSA$	35

(table 1) which corresponds closely to the % 125 I-labelled protease taken up into higher mol. wt complexes (as seen in fig.2). The specificity of the affinity column for the retention only of material bound to $\overline{C1}$ In was confirmed by showing that all radioactive material retained on this column, when examined on SDS-polyacrylamide gels, behaved as $\overline{C1r}-\overline{C1}$ In, or as appropriate, $\overline{C1s}-\overline{C1}$ In complexes (c f. fig.3). The molecular weight of $\overline{C1}$ In is sufficiently distinct from those of other well-characteristed protease inhibitors that simple analysis by SDS-polyacrylamide gel electrophoresis is adequate to identify complexes of $\overline{C1}$ In with a known protease. The mobilities of complexes of $\overline{C1r}$ and $\overline{C1s}$ with $\overline{C1}$ In in this electrophoresis system have been described [5]




Fig.3 Pattern of migration of 125 I-labelled polypeptide chains of $\overline{C1r}$, $\overline{C1s}$ and their complexes with $\overline{C1}$ In on SDS-polyacrylamide gels. 15 000-18 000 cpm was loaded onto each gel Alkylated samples ($--\circ-$) and reduced and alkylated samples ($--\circ-$) are shown (A) $\overline{C1s}$, (B) $\overline{C1r}$, (C) $\overline{C1s}$ - $\overline{C1}$ In complex, (D) $\overline{C1r}$ - $\overline{C1}$ In complex The molecular weight scale refers only to reduced samples $\overline{C1s}$ A, $\overline{C1r}$ A and $\overline{C1s}$ B, $\overline{C1r}$ B A chain of $\overline{C1r}$, $\overline{C1s}$ and B chain of $\overline{C1r}$, $\overline{C1s}$, respectively.




Fig.4 Second gel filtration analysis radioactive material not retained on Sepharose 6B-anti $\overline{C1}$ In The elution profile of radioactivity is shown. Conditions, and identification of samples as in fig.2

Re-examination on Ultrogel AcA 34 of the remaining radioactive material which did not bind to the affinity column showed (fig.4) that all of this material behaved as free $\overline{C1r}$ or $\overline{C1s}$. This was confirmed by subsequent analysis on SDS polyacrylamide gels (c.f. fig.3). In some experiments, up to 10% of the remaining free $\overline{C1r}$ was seen to have undergone a proteolytic degradation similar to that in [17].

These results demonstrate that $C\overline{1}$ In 1s the only protease inhibitor in plasma or serum which forms a stable complex with $C\overline{1}r$ or $C\overline{1}s$. Incubation of 25 μg additions of these proteases, which do not exceed the inhibitory capacity of $C\overline{1}$ In 1n plasma, result in uptake of most of the protease into higher molecular weight complexes. When the addition of protease exceeds the capacity of $C\overline{1}$ In, however, much of the added protease remains in the free state. All higher molecular weight complexes formed were removed by

chromatography on anti-CI In, leaving only free CIr and CIs. Since in these experiments recovery of radioactivity at each step was >95%, non-specific loss of other protease—protease inhibitor complexes is unlikely to influence the results. The method used here, gel filtration before and after affinity chromatography using antibody against the principal known inhibitor, is generally applicable as a means to simplify systems where several proteases and inhibitors may be involved.

C1 In is likely therefore to be the principal inhibitor of Clr and Cls in vivo, although cellular protease inhibitors may also be involved. Evidence has been presented [18] that C1 In is the major in vivo control of C1s. C1s has also been reported to be inhibited by very high concentrations of heparin and antithrombin III [19]. The experiments described above, however, were done in heparin-free conditions. The result obtained here confirms observations that C1r is not inhibited by α₂ macroglobulin, inter-α-trypsin inhibitor and α_1 antitrypsin [20]. Similarly, C1s has been reported to be unreactive towards α_1 antitrypsin [19] and α_2 antiplasmin [21]. Thus CIr and CIs, unlike the many other plasma proteases are inhibited by only one of the plasma inhibitors. This is compatible with the very restricted proteolytic specificity of these two enzymes [3,9].

An anomaly in the behaviour of C1r was also noted in these experiments. Since $\overline{C1r}$ is a dimer [3] it may be expected to form complexes containing either one or two molecules of C1 In. The C1r dimer dissociates on SDS-polyacrylamide gel electrophoresis, and thus complexes of type $\overline{C1r_2}$ – $\overline{C1}$ In₁ should dissociate into free $\overline{C1}$ r plus $\overline{C1}$ r₁ $-\overline{C1}$ In₁ complexes in SDS. Analysis on SDS-polyacrylamide gels of material retained on the affinity column after incubation of excess $C\overline{1}r$ (250 µg) with plasma, showed only $C\overline{1}r_1$ – $\overline{C1}$ In complexes, and no free $\overline{C1}$ r. Thus in conditions where CIr is in excess of CI In, which should favour formation of $\overline{C1r_2}$ – $\overline{C1}$ In₁, thus type of complex was not detected. Sucrose density gradient and gel filtration analysis of mixtures of excess $\overline{C1}r + \overline{C1}$ In also suggest that only complexes of the type Clr₂-Cl In₂ are formed. This result may indicate cooperativity in the reaction of C1r with C1 In. The techniques presently available for investigating the kinetics of this reaction (as seen in fig.1b) are not sufficiently rapid to confirm this possibility.

Acknowledgements

We thank Dr E. Sim for helpful discussion. This work was supported by the CNRS (ERA no. 695), INSERM (AT 487780), the DGRST (contracts 76.7.1194 and 76.7.1195) and the Fondation pour la Recherche Médicale. R. B. Sim thanks the MRC (England) and INSERM for an exchange fellowship.

References

- [1] Sim, R B and Porter, R R (1976) Biochem. Soc Trans. 4, 127-129
- [2] Dodds, A. W., Sim, R. B., Porter, R. R. and Kerr, M. A. (1978) Biochem. J. in press.
- [3] Sim, R B, Porter, R R, Reid, K. B M and Gigli, I (1977) Biochem. J 163, 219-227
- [4] Reboul, A, Arlaud, G. J., Sim, R. B. and Colomb, M. G. (1977) FEBS Lett. 79, 45-50.
- [5] Arlaud, G. J., Reboul, A., Sim, R. B. and Colomb, M. G. (1979) Biochim. Biophys. Acta, in press
- [6] Harpel, P. C, Mosesson, M W and Cooper, N R (1975) in Proteases and Biological Control (Reich, E et al. eds) pp 387-404, Cold Spring Harbor Lab, New York
- [7] Heimburger, N (1975) in Proteases and Biological Control (Reich, E et al) pp 367-386, Cold Spring Harbor Lab., New York
- [8] Wiman, B and Collen, D (1978) Eur J Biochem. 84, 573-578.
- [9] Gigli, I, Porter, R R and Sim, R B (1976) Biochem J 157, 541-548
- [10] Arlaud, G J, Sim, R B, Duplaa, A-M and Colomb, M G (1979) submitted
- [11] Harpel, P C (1976) Methods Enzymol 45, 751-760
- [12] Arlaud, G J, Reboul, A, Meyer, C M and Colomb, M G. (1977) Biochim. Biophys Acta 485, 215-226
- [13] Heusser, C, Boesman, M., Nordin, J H and Isliker, H (1973) J Immunol. 110, 820-828
- [14] Naff, G B. and Ratnoff, O D (1968) J Exp. Med 128, 571-593
- [15] Sim, R B and Colomb, M G (1977) Ann Immunol (Inst. Pasteur) 128C, 946-947
- [16] Bartholomew, R. M and Esser, A F (1977) J Immunol 119, 1916-1922
- [17] Okamura, K and Fujii, S (1978) Biochim. Biophys Acta 534, 258-266
- [18] Ratnoff, O D and Lepow, I H. (1963) J Exp Med 118, 681-692
- [19] Ogston, D, Murray, J and Crawford, G P M (1976) Thrombosis Res 9, 217-222.
- [20] Ziccardı, R. J and Cooper, N R (1976) J Immunol 116,498-503
- [21] Moroi, M and Aoki, N (1977) J Biochem. 82, 969-972.